LivingGLP1
Descriptive only

Death by suicide

Type 2 diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
43
Randomized trials
49
Treatments
13,687
Participants
1
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 43 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
DULA_SC_0p75MG_QWDULA_SC_1p5MG_QWEMPAGLIFLOZINEXENER_SC_2MG_QWEXEN_SC_10UG_BIDEXEN_SC_5UG_BIDGLIMEPIRIDEIDEGLIRA_SC_TIT_QDIGLARLIXI2_SC_TIT_QDINS_DEGLUDECINS_GLARGINEINS_LISPROINS_PREMIXLIRA_SC_0p9MG_QDLIRA_SC_1p2MG_QDLIRA_SC_1p8MG_QDLIXI_SC_20UG_QDLIXI_SC_30UG_BIDLIXI_SC_30UG_QDLIXI_SC_5UG_BIDLIXI_SC_5UG_QDLOTI_PO_140MG_QDLOTI_PO_200MG_QDLOTI_PO_260MG_QDLOTI_PO_80MG_QDMAZD_SC_4p5MG_QWMAZD_SC_6MG_QWORFO_PO_12MG_QDORFO_PO_24MG_QDORFO_PO_45MG_QDPEGLOX_SC_0p2MG_QWPEGLOX_SC_300UG_QWPEGLOX_SC_400UG_QWPLACEBOSEMA_PO_14MG_QDSEMA_PO_3MG_QDSEMA_PO_7MG_QDSEMA_SC_0p5MG_QWSEMA_SC_1p0MG_QWSITAGLIPTINSTANDARD_CARETASP_SC_10MG_QWTASP_SC_20MG_QWTASP_SC_30MG_QWTIRZ_SC_10MG_QWTIRZ_SC_12MG_QWTIRZ_SC_15MG_QWTIRZ_SC_1MG_QWTIRZ_SC_5MG_QW
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 8.5 or less
  • FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 35 or less
  • NoteOutcome assessment, time point: selected time points span 5 to 57 weeks
  • NoteOutcome assessment, analysis set: mixed: completers 1, full_analysis 2, modified_itt 3, other 3, randomized 4, safety 30
  • NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, C-SSRS post baseline category 1, Grade 3, needing third party assistance 1, Hypoglycemia adverse event of special interest 1, hypoglycemia requiring medical assistance 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, minor: symptoms with glucose below 3.0 mmol/L, self treated 1, not stated 20, plasma glucose 54 mg/dL or lower 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe hypoglycemia 1, severe hypoglycemia needing assistance of another person 1, Severe hypoglycemia needing assistance with glucose below 36 mg/dL or prompt recovery 1, Severe hypoglycemia requiring assistance of another person 1, severe hypoglycemia, undefined 1, severe symptomatic hypoglycemia needing assistance 1, severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery 1, severe, requiring assistance of another person 2, symptomatic hypoglycemia confirmed below 3.3 mmol/L 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, symptomatic mild hypoglycemia, no glucose threshold printed 1, TEAE leading to death 1, Zero implied by no hypoglycemia episodes of any kind 1
  • NoteOutcome assessment, adjudicated: mixed: not stated 42, yes 1
  • NoteOutcome assessment, proportion method: mixed: not stated 41, observed 2
  • NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 42, while_on_treatment 1
  • NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 42, treatment_policy 1
  • NoteRisk of bias, blinding: mixed: double_blind 27, open_label 14, single_blind 2
  • NoteRisk of bias, funding: mixed: industry 37, mixed 3, non_industry 3
  • NoteData handling, input conversions: arms_combined 3, printed_denominator 11
Comparability items per trial
Trialanalysis settime weeksdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
NCT03131687safety30severe hypoglycemia needing assistance of another personnot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT02325960safety16not statednot statednot statednot statednot statednot statedopen_labelmixed2015age 18 to 70; BMI 24 or more; HbA1c 7.0 to 10.0 percent; metformin 1.5 g/day or more
PIONEER 4safety57not statednot statednot statednot statednot statednot stateddouble_blindindustry2016Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
MAGNA VICTORIAsafety26not statednot statednot statednot statednot statednot stateddouble_blindmixed2015South Asian descent; age 18 to 74; BMI 23 or more; HbA1c 6.5 to 11.0 percent
Lixilan-O-APsafety24.43not statednot statednot statednot statednot statednot statedopen_labelindustry2019adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
PIONEER 10safety57not statednot statedyesnot statedwhile_on_treatmenttreatment_policysingle_blindindustry2017Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT03951753safety32not statednot statednot statednot statednot statednot stateddouble_blindindustry2019age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent
NCT00765817full_analysis30minor: symptoms with glucose below 3 mmol/L, self treated or resolvednot statednot statednot statednot statednot stateddouble_blindindustry2008adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT05579977safety28C-SSRS post baseline categorynot statednot statednot statednot statednot stateddouble_blindindustry2022age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
GETGOAL-L-ASIAsafety24severe symptomatic hypoglycemia needing assistancenot statednot statednot statednot statednot stateddouble_blindindustry2009age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT00960661other30minor: symptoms with glucose below 3.0 mmol/L, self treatednot statednot statedobservednot statednot statedopen_labelindustry2009age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
NCT00577824full_analysis24Severe hypoglycemia requiring assistance of another personnot statednot statednot statednot statednot stateddouble_blindindustry2008age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
GetGoal-Duo1safety24symptomatic hypoglycemia confirmed below 3.3 mmol/Lnot statednot statedobservednot statednot stateddouble_blindindustry2009T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT01558271safety52not statednot statednot statednot statednot statednot stateddouble_blindindustry2012Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
AWARD-CHN1safety26severe, requiring assistance of another personnot statednot statednot statednot statednot stateddouble_blindindustry2012age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8modified_itt24not statednot statednot statednot statednot statednot stateddouble_blindindustry2013age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
SUSTAINsafety35Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptomsnot statednot statednot statednot statednot stateddouble_blindindustry2017Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
AWARD-CHN2safety52severe, requiring assistance of another personnot statednot statednot statednot statednot statedopen_labelindustry2012age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
NCT00299871safety13.43symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydratenot statednot statednot statednot statednot stateddouble_blindindustry2006age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
NCT02212067randomized17not statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to 64; HbA1c 6.5 to 9.0 percent; BMI 20 to 35; diet and exercise or metformin
NCT00460941safety12severe hypoglycemia, undefinednot statednot statednot statednot statednot stateddouble_blindindustry2007age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45
NCT00744926safety24severe hypoglycemianot statednot statednot statednot statednot stateddouble_blindindustry2008age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
ELEGANTrandomized26Grade 3, needing third party assistancenot statednot statednot statednot statednot statedopen_labelindustry2012age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
PIONEER 11safety31ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all armsnot statednot statednot statednot statednot stateddouble_blindindustry2019age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
SUSTAIN™ 5safety35not statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
DUAL™ I Japansafety53not statednot statednot statednot statednot statednot statedopen_labelindustry2015Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug
NCT05086445safety14Hypoglycemia adverse event of special interestnot statednot statednot statednot statednot stateddouble_blindindustry2021Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
LIXILAN JP-O1safety52.43TEAE leading to deathnot statednot statednot statednot statednot statedopen_labelindustry2016insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
SUSTAIN™safety35not statednot statednot statednot statednot statednot statedopen_labelindustry2014Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
NCT02288273modified_itt14not statednot statednot statednot statednot statednot stateddouble_blindindustry2014age 18 to 75; T2D on metformin 1500 mg or more; HbA1c 7.0 to 10.0 percent; BMI 45 or less
Lixilan-L-CNsafety30.43not statednot statednot statednot statednot statednot statedopen_labelindustry2019Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
GETGOAL-Msafety24severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recoverynot statednot statednot statednot statednot stateddouble_blindindustry2008type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT01455441completers16Zero implied by no hypoglycemia episodes of any kindnot statednot statednot statednot statednot stateddouble_blindindustry2011age over 18; HbA1c 7 to 11 percent; BMI over 25; diet or metformin; sedentary
NCT03311724modified_itt16plasma glucose 54 mg/dL or lowernot statednot statednot statednot statednot stateddouble_blindindustry2017age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT04466904safety20not statednot statednot statednot statednot statednot stateddouble_blindindustry2020age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
NCT00700817other52not statednot statednot statednot statednot statednot statedopen_labelindustry2008age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
S002858randomized24not statednot statednot statednot statednot statednot stateddouble_blindindustryT2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S002885other12symptomatic mild hypoglycemia, no glucose threshold printednot statednot statednot statednot statednot statedopen_labelnon_industry2019age 20 to 75; HbA1c 7.0 or more on metformin and glimepiride; eGFR 30 or more
S002928safety24not statednot statednot statednot statednot statednot statedsingle_blindnon_industry2022age 18 to 65; BMI 50 or more; type 2 diabetes
S002984randomized24not statednot statednot statednot statednot statednot statedopen_labelmixed2020T2D age 45 or older; HbA1c 7.0 to 11.0 percent; metformin at least 3 months
S002992safety26.43not statednot statednot statednot statednot statednot statedopen_labelindustryadults 18 or older; HbA1c 7.5 to 10 percent; BMI 20 to less than 40; basal insulin 20 to 50 U plus metformin with or without SGLT2i
S003047safety6.57Severe hypoglycemia needing assistance with glucose below 36 mg/dL or prompt recoverynot statednot statednot statednot statednot stateddouble_blindindustry2006age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003079safety5hypoglycemia requiring medical assistancenot statednot statednot statednot statednot statedopen_labelnon_industry2010age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
NCT03131687A1PLACEBO30arm, events0 / 51R0016215:Table 3
NCT03131687A2TIRZ_SC_1MG_QW30arm, events0 / 53R0016215:Table 3
NCT03131687A3TIRZ_SC_5MG_QW30arm, events0 / 55R0016215:Table 3
NCT03131687A4TIRZ_SC_10MG_QW30arm, events0 / 52R0016215:Table 3
NCT03131687A5TIRZ_SC_15MG_QW30arm, events0 / 53R0016215:Table 3
NCT03131687A6DULA_SC_1p5MG_QW30arm, events0 / 54R0016215:Table 3
NCT02325960A1EXEN_SC_10UG_BID16arm, events0 / 22R0024438:Results
NCT02325960A2INS_GLARGINE16arm, events0 / 23R0024438:Results
PIONEER 4A1SEMA_PO_14MG_QD57arm, events0 / 285R0015836:Supplement Table S6
PIONEER 4A2LIRA_SC_1p8MG_QD57arm, events0 / 284R0015836:Supplement Table S6
PIONEER 4A3PLACEBO57arm, events0 / 142R0015836:Supplement Table S6
MAGNA VICTORIAA1LIRA_SC_1p8MG_QD26arm, events0 / 22R0020542:Results
MAGNA VICTORIAA2PLACEBO26arm, events0 / 25R0020542:Results
Lixilan-O-APA1IGLARLIXI2_SC_TIT_QD24.43arm, events0 / 351R0013321:Results
Lixilan-O-APA2INS_GLARGINE24.43arm, events0 / 350R0013321:Results
Lixilan-O-APA3LIXI_SC_20UG_QD24.43arm, events0 / 177R0013321:Results
PIONEER 10A1SEMA_PO_3MG_QD57arm, events0 / 131R0018421:Table 2
PIONEER 10A2SEMA_PO_7MG_QD57arm, events0 / 132R0018421:Table 2
PIONEER 10A3SEMA_PO_14MG_QD57arm, events0 / 130R0018421:Table 2
PIONEER 10A4DULA_SC_0p75MG_QW57arm, events0 / 65R0018421:Table 2
NCT00765817A1EXEN_SC_10UG_BID30arm, events0 / 138R0027069:Table 3
NCT00765817A2PLACEBO30arm, events0 / 123R0027069:Results
NCT05579977A10LOTI_PO_140MG_QD28arm, events0 / 64registry:outcomes
NCT05579977A11+A12LOTI_PO_200MG_QD28arm, events0 / 131arms_combinedregistry:outcomes
NCT05579977A13LOTI_PO_260MG_QD28arm, events0 / 64registry:outcomes
NCT05579977A8PLACEBO28arm, events0 / 64registry:outcomes
NCT05579977A9LOTI_PO_80MG_QD28arm, events0 / 66registry:outcomes
GETGOAL-L-ASIAA1LIXI_SC_20UG_QD24arm, events0 / 154R0022626:Results
GETGOAL-L-ASIAA2PLACEBO24arm, events1 / 157R0022626:Results
NCT03951753A1TIRZ_SC_15MG_QW32arm, events0 / 45registry:adverse_events
NCT03951753A2SEMA_SC_1p0MG_QW32arm, events0 / 44registry:adverse_events
NCT03951753A3PLACEBO32arm, events0 / 28registry:adverse_events
NCT00960661A1EXEN_SC_10UG_BID30arm, events0 / 316R0016788:Results
NCT00960661A2INS_LISPRO30arm, events0 / 321R0016788:Figure 1
NCT00577824A1PLACEBO24arm, events0 / 36R0018881:Results
NCT00577824A2EXEN_SC_5UG_BID24arm, events0 / 72R0018881:Results
NCT00577824A3EXEN_SC_10UG_BID24arm, events0 / 73R0018881:Results
GetGoal-Duo1A1PLACEBO24arm, events0 / 223R0026107:Results
GetGoal-Duo1A2LIXI_SC_20UG_QD24arm, events0 / 223R0026107:Results
NCT01558271A1DULA_SC_0p75MG_QW52arm, events0 / 281R0011754:Table 2
NCT01558271A2LIRA_SC_0p9MG_QD52arm, events0 / 141R0011754:Table 2
AWARD-CHN1A1DULA_SC_1p5MG_QW26arm, events0 / 244R0014229:Table 2
AWARD-CHN1A3GLIMEPIRIDE26arm, events0 / 245R0014229:Table 2
AWARD-8A1DULA_SC_1p5MG_QW24arm, events0 / 240R0016038:Results
AWARD-8A2PLACEBO24arm, events0 / 60R0016038:Results
SUSTAINA1SEMA_SC_0p5MG_QW35arm, events0 / 288R0014802:Results
SUSTAINA3SITAGLIPTIN35arm, events0 / 290R0014802:Table 3
AWARD-CHN2A2DULA_SC_0p75MG_QW52arm, events0 / 257R0023722:Table 2
AWARD-CHN2A3INS_GLARGINE52arm, events0 / 259R0023722:Table 2
NCT00299871A2LIXI_SC_5UG_QD13.43arm, events0 / 55R0021613:Table 3
NCT00299871A6LIXI_SC_5UG_BID13.43arm, events0 / 53R0021613:Table 3
NCT00299871A9LIXI_SC_30UG_BID13.43arm, events0 / 54R0021613:Table 3
NCT02212067A1SEMA_SC_1p0MG_QW17arm, events0 / 37R0021892:Supplement Table 2
NCT02212067A2PLACEBO17arm, events0 / 38R0021892:Supplement Table 2
NCT00460941A2TASP_SC_20MG_QW12arm, events0 / 32printed_denominatorR0021258:Results
NCT00460941A3TASP_SC_30MG_QW12arm, events0 / 33printed_denominatorR0021258:Results
NCT00744926A1PLACEBO24arm, events0 / 123printed_denominatorR0025346:Results
NCT00744926A2TASP_SC_10MG_QW24arm, events0 / 116printed_denominatorR0025346:Results
NCT00744926A3TASP_SC_20MG_QW24arm, events0 / 129printed_denominatorR0025346:Results
ELEGANTA1LIRA_SC_1p8MG_QD26arm, events0 / 26R0025175:Results
ELEGANTA2STANDARD_CARE26arm, events0 / 24R0025175:Results
PIONEER 11A1SEMA_PO_3MG_QD31arm, events0 / 130R0019663:Table 3
PIONEER 11A2SEMA_PO_7MG_QD31arm, events0 / 130R0019663:Table 3
PIONEER 11A3SEMA_PO_14MG_QD31arm, events0 / 130R0019663:Table 3
PIONEER 11A4PLACEBO31arm, events0 / 131R0019663:Table 3
SUSTAIN™ 5A1SEMA_SC_0p5MG_QW35arm, events0 / 132R0012671:Table 2
SUSTAIN™ 5A2SEMA_SC_1p0MG_QW35arm, events0 / 132R0012671:Table 2
SUSTAIN™ 5A3PLACEBO35arm, events0 / 133R0012671:Table 2
DUAL™ I JapanA1IDEGLIRA_SC_TIT_QD53arm, events0 / 275registry:adverse_events
DUAL™ I JapanA2INS_DEGLUDEC53arm, events0 / 271registry:adverse_events
DUAL™ I JapanA3LIRA_SC_1p8MG_QD53arm, events0 / 273registry:adverse_events
NCT05086445A1PLACEBO14arm, events0 / 11R0003844:Table 2
NCT05086445A2ORFO_PO_12MG_QD14arm, events0 / 14R0003844:Table 2
NCT05086445A3ORFO_PO_24MG_QD14arm, events0 / 17R0003844:Table 2
NCT05086445A4ORFO_PO_45MG_QD14arm, events0 / 18R0003844:Table 2
LIXILAN JP-O1A1IGLARLIXI2_SC_TIT_QD52.43arm, events0 / 161R0015751:Table 3
LIXILAN JP-O1A2LIXI_SC_20UG_QD52.43arm, events0 / 160R0015751:Results
SUSTAIN™A1SEMA_SC_0p5MG_QW35arm, events0 / 103R0014736:Table 2
SUSTAIN™A2SEMA_SC_1p0MG_QW35arm, events0 / 102R0014736:Table 2
SUSTAIN™A3SITAGLIPTIN35arm, events0 / 103R0014736:Table 2
NCT02288273A1EXENER_SC_2MG_QW14arm, events0 / 61R0025397:Results
NCT02288273A2PLACEBO14arm, events0 / 56R0025397:Results
Lixilan-L-CNA1IGLARLIXI2_SC_TIT_QD30.43arm, events0 / 212R0014540:Table 3
Lixilan-L-CNA2INS_GLARGINE30.43arm, events0 / 214R0014540:Table 3
GETGOAL-MA1+A2LIXI_SC_20UG_QD24arm, events0 / 510arms_combinedR0025872:Table 2
GETGOAL-MA3PLACEBO24arm, events0 / 170printed_denominatorR0025872:Table 2
NCT01455441A1LIRA_SC_1p8MG_QD16arm, events0 / 18R0010221:Results
NCT01455441A2PLACEBO16arm, events0 / 16R0010221:Results
NCT03311724A1PLACEBO16arm, events0 / 26R0010282:Table 2
NCT03311724A2TIRZ_SC_12MG_QW16arm, events0 / 29R0010282:Table 2
NCT03311724A3+A4TIRZ_SC_15MG_QW16arm, events0 / 56arms_combinedR0010282:Table 2
NCT04466904A2MAZD_SC_4p5MG_QW20arm, events0 / 8R0009340:Table 2
NCT04466904A3MAZD_SC_6MG_QW20arm, events0 / 8R0009340:Table 2
NCT04466904A4DULA_SC_1p5MG_QW20arm, events0 / 6printed_denominatorR0009340:Table 2
NCT04466904A5PLACEBO20arm, events0 / 12printed_denominatorR0009340:Table 2
NCT00700817A1LIRA_SC_1p2MG_QD52arm, events0 / 225R0024199:Table 2
NCT00700817A2LIRA_SC_1p8MG_QD52arm, events0 / 221R0024199:Table 2
NCT00700817A3SITAGLIPTIN52arm, events0 / 219R0024199:Table 2
S002858A1LIXI_SC_20UG_QD24arm, events0 / 51R0001573:Supplement Table S2
S002858A2PLACEBO24arm, events0 / 50R0001573:Supplement Table S2
S002885A1DULA_SC_1p5MG_QW12arm, events0 / 13R0003420:Results
S002885A2EMPAGLIFLOZIN12arm, events0 / 12R0003420:Results
S002928A1PLACEBO24arm, events0 / 41R0007034:Results
S002928A2PEGLOX_SC_300UG_QW24arm, events0 / 41R0007034:Results
S002928A3PEGLOX_SC_400UG_QW24arm, events0 / 41R0007034:Results
S002984A1PEGLOX_SC_0p2MG_QW24arm, events0 / 39R0011969:Supplement Table S2
S002984A2INS_GLARGINE24arm, events0 / 39R0011969:Supplement Table S2
S002992A1IGLARLIXI2_SC_TIT_QD26.43arm, events0 / 443R0010673:Results
S002992A2INS_PREMIX26.43arm, events0 / 444R0010673:Results
S003047A1LIXI_SC_30UG_QD6.57arm, events0 / 39printed_denominatorR0016337:Results
S003047A2LIXI_SC_30UG_BID6.57arm, events0 / 41printed_denominatorR0016337:Results
S003047A3PLACEBO6.57arm, events0 / 40printed_denominatorR0016337:Results
S003079A1EXEN_SC_10UG_BID5arm, events0 / 18R0025923:Results
S003079A2STANDARD_CARE5arm, events0 / 18R0025923:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab